Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Safety and PK Study of LY3372689 in Healthy Participants
NCT03819270Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2019
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing LY3372689 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) at 12 weeks. Started Feb 2019; status: completed.
02
Drugs
ceperognastat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03819270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819270.